Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon
On 10 November, Novo announced plans to invest DKK42 billion (5 billion) to upgrade its manufacturing facilities to support GLP-1 products as well as other treatments for chronic diseases
In comparison, the patients lost 17.5% of their body weight on average at 24 weeks and 24.2% of weight after 48 weeks in phase 2 clinical trials with retatrutide
Overall though, its more about getting protein throughout the dayand less about exactly which foods provide it
Retatrutide adds glucagon receptor activation, which plays a role in fat breakdown and energy expenditure
US$ 20.33
US$ 25.99
US$ 23.87
US$ 27.06
